Search

Displaying results 3001 - 3010 of 8697 in total
  1. Drug

    Mafenide

    go.drugbank.com/drugs/DB06795
    ApprovedVet approvedWithdrawn

    In November 2022, the use of mafenide acetate (powder for 5% topical solution) was withdrawn by the FDA due to an unresolved confirmatory study required to fulfill the accelerated approval requirements

  2. Drug

    Haloperidol

    go.drugbank.com/drugs/DB00502
    ApprovedInvestigational

    Inter-ethnic and pharmacogenetic differences in haloperidol metabolism may possibly explain these observations. … Interestingly, in vivo pharmacogenetic studies have demonstrated that the metabolism of haloperidol may be modulated by genetically determined polymorphic _CYP2D6_ activity.

    Categories: P-glycoprotein inhibitors, P-glycoprotein substratesSynonyms: 1-(3-p-fluorobenzoylpropyl)-4-p-chlorophenyl-4-hydroxypiperidine, γ-(4-(p-chlorophenyl)-4-hydroxpiperidino)-p-fluorbutyrophenone
  3. Drug

    Bezlotoxumab

    go.drugbank.com/drugs/DB13140
    Approved

    [L46976] On November 22, 2016, the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended the granting of a marketing authorization.

    Categories: Antiinfectives for Systemic Use
  4. Drug

    Thrombin alfa

    go.drugbank.com/drugs/DB11572
    Approved

    Thrombin Alfa is a human coagulation protein produced via recombinant DNA technology from a genetically modified CHO cell line. Thrombin Alfa is identical in amino acid sequence and structurally similar to naturally occurring human throm...

  5. Drug

    Potassium cation

    go.drugbank.com/drugs/DB01345
    Approved

    The ability of cells to produce electrical discharge is critical for body functions such as neurotransmission, muscle contraction, and heart function. … Potassium is also an essential mineral needed to regulate water balance, blood pressure and levels of acidity.

  6. Drug

    TG100-115

    go.drugbank.com/drugs/DB05552
    Investigational

    An NSAID that inhibits PI-3K gamma and delta.

  7. Drug

    Atacicept

    go.drugbank.com/drugs/DB06399
    ApprovedInvestigational

    [L63797] The US FDA granted accelerated approval to atacicept-vymj on July 7, 2026, to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression. … [L63797] Reducing BAFF- and APRIL-mediated signaling lowers production of galactose-deficient IgA1, an aberrant antibody whose deposition in the kidney drives IgA nephropathy.

  8. Drug

    Thiothixene

    go.drugbank.com/drugs/DB01623
    Approved

    A thioxanthine used as an antipsychotic agent. Its effects are similar to the phenothiazine antipsychotics.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  9. Drug

    Ecallantide

    go.drugbank.com/drugs/DB05311
    Approved

    Ecallantide is marketed by FDA and EMA under the trade name Kalbitor for subcutaneous injection. … Ecallantide is a potent and selective human plasma kallikrein inhibitor that is indicated for the symptomatic treatment of hereditary angioedema.

  10. Drug

    Icosapent ethyl

    go.drugbank.com/drugs/DB08887
    ApprovedInvestigationalNutraceutical

    It is used as an adjunct therapy for severe hypertriglyceridemia (TG levels > 500 mg/dL) and to reduce the risk of cardiovascular events in certain patients with elevated triglycerides.